S&P 500   4,242.84 (+0.85%)
DOW   33,540.35 (+0.61%)
QQQ   327.83 (+1.16%)
AAPL   170.88 (+1.42%)
MSFT   289.28 (+0.79%)
META   180.45 (+1.67%)
GOOGL   120.03 (+1.00%)
AMZN   141.22 (+0.41%)
TSLA   882.00 (+2.57%)
NVDA   184.70 (+2.94%)
NIO   21.01 (+0.91%)
BABA   94.13 (-0.78%)
AMD   100.39 (+2.31%)
MU   64.41 (+3.35%)
T   18.17 (+0.72%)
CGC   3.24 (+2.86%)
GE   79.04 (+0.18%)
F   16.00 (+1.07%)
DIS   120.53 (+2.41%)
AMC   25.99 (+2.08%)
PYPL   100.83 (+1.74%)
PFE   49.71 (+2.94%)
NFLX   246.24 (+1.46%)
S&P 500   4,242.84 (+0.85%)
DOW   33,540.35 (+0.61%)
QQQ   327.83 (+1.16%)
AAPL   170.88 (+1.42%)
MSFT   289.28 (+0.79%)
META   180.45 (+1.67%)
GOOGL   120.03 (+1.00%)
AMZN   141.22 (+0.41%)
TSLA   882.00 (+2.57%)
NVDA   184.70 (+2.94%)
NIO   21.01 (+0.91%)
BABA   94.13 (-0.78%)
AMD   100.39 (+2.31%)
MU   64.41 (+3.35%)
T   18.17 (+0.72%)
CGC   3.24 (+2.86%)
GE   79.04 (+0.18%)
F   16.00 (+1.07%)
DIS   120.53 (+2.41%)
AMC   25.99 (+2.08%)
PYPL   100.83 (+1.74%)
PFE   49.71 (+2.94%)
NFLX   246.24 (+1.46%)
S&P 500   4,242.84 (+0.85%)
DOW   33,540.35 (+0.61%)
QQQ   327.83 (+1.16%)
AAPL   170.88 (+1.42%)
MSFT   289.28 (+0.79%)
META   180.45 (+1.67%)
GOOGL   120.03 (+1.00%)
AMZN   141.22 (+0.41%)
TSLA   882.00 (+2.57%)
NVDA   184.70 (+2.94%)
NIO   21.01 (+0.91%)
BABA   94.13 (-0.78%)
AMD   100.39 (+2.31%)
MU   64.41 (+3.35%)
T   18.17 (+0.72%)
CGC   3.24 (+2.86%)
GE   79.04 (+0.18%)
F   16.00 (+1.07%)
DIS   120.53 (+2.41%)
AMC   25.99 (+2.08%)
PYPL   100.83 (+1.74%)
PFE   49.71 (+2.94%)
NFLX   246.24 (+1.46%)
S&P 500   4,242.84 (+0.85%)
DOW   33,540.35 (+0.61%)
QQQ   327.83 (+1.16%)
AAPL   170.88 (+1.42%)
MSFT   289.28 (+0.79%)
META   180.45 (+1.67%)
GOOGL   120.03 (+1.00%)
AMZN   141.22 (+0.41%)
TSLA   882.00 (+2.57%)
NVDA   184.70 (+2.94%)
NIO   21.01 (+0.91%)
BABA   94.13 (-0.78%)
AMD   100.39 (+2.31%)
MU   64.41 (+3.35%)
T   18.17 (+0.72%)
CGC   3.24 (+2.86%)
GE   79.04 (+0.18%)
F   16.00 (+1.07%)
DIS   120.53 (+2.41%)
AMC   25.99 (+2.08%)
PYPL   100.83 (+1.74%)
PFE   49.71 (+2.94%)
NFLX   246.24 (+1.46%)
NASDAQ:BMRN

BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

$94.50
-0.57 (-0.60%)
(As of 08/12/2022 11:40 AM ET)
Add
Compare
Today's Range
$94.20
$95.20
50-Day Range
$71.48
$96.00
52-Week Range
$70.73
$97.76
Volume
11,332 shs
Average Volume
1.08 million shs
Market Capitalization
$17.53 billion
P/E Ratio
363.48
Dividend Yield
N/A
Price Target
$110.93

BioMarin Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
17.1% Upside
$110.93 Price Target
Short Interest
Bearish
6.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
0.65mentions of BioMarin Pharmaceutical in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$2.02 M Sold Last Quarter
Proj. Earnings Growth
189.13%
From $0.92 to $2.66 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

235th out of 1,112 stocks

Pharmaceutical Preparations Industry

112th out of 544 stocks

BMRN stock logo

About BioMarin Pharmaceutical (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Wall Street Analyst Weigh In

A number of equities analysts have commented on BMRN shares. SVB Leerink boosted their price target on shares of BioMarin Pharmaceutical from $115.00 to $122.00 and gave the stock an "outperform" rating in a research note on Thursday, August 4th. Cantor Fitzgerald began coverage on shares of BioMarin Pharmaceutical in a report on Tuesday, July 12th. They set an "overweight" rating and a $110.00 price target for the company. Piper Sandler increased their price objective on shares of BioMarin Pharmaceutical from $125.00 to $128.00 and gave the company an "overweight" rating in a research report on Tuesday. Morgan Stanley increased their price objective on shares of BioMarin Pharmaceutical from $113.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, August 4th. Finally, Barclays upped their target price on shares of BioMarin Pharmaceutical from $112.00 to $125.00 and gave the company an "overweight" rating in a research note on Thursday, August 4th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $110.93.

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN traded down $0.93 on Thursday, reaching $95.07. 1,226,746 shares of the stock traded hands, compared to its average volume of 1,245,007. BioMarin Pharmaceutical has a 12 month low of $70.73 and a 12 month high of $97.76. The firm's fifty day simple moving average is $83.95 and its 200 day simple moving average is $82.44. The company has a market cap of $17.63 billion, a price-to-earnings ratio of 365.74, a P/E/G ratio of 2.08 and a beta of 0.33. The company has a quick ratio of 3.69, a current ratio of 5.42 and a debt-to-equity ratio of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Rating) last issued its earnings results on Wednesday, August 3rd. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.11 by $0.04. BioMarin Pharmaceutical had a return on equity of 1.78% and a net margin of 2.83%. During the same period in the previous year, the firm earned $0.23 earnings per share. As a group, research analysts predict that BioMarin Pharmaceutical will post 0.92 EPS for the current fiscal year.

Insider Buying and Selling at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 7,398 shares of the company's stock in a transaction on Friday, July 8th. The stock was sold at an average price of $90.00, for a total transaction of $665,820.00. Following the transaction, the executive vice president now owns 58,941 shares of the company's stock, valued at approximately $5,304,690. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, EVP George Eric Davis sold 7,398 shares of the company's stock in a transaction on Friday, July 8th. The shares were sold at an average price of $90.00, for a total value of $665,820.00. Following the completion of the transaction, the executive vice president now directly owns 58,941 shares of the company's stock, valued at approximately $5,304,690. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jeffrey Robert Ajer sold 1,308 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $78.94, for a total transaction of $103,253.52. Following the transaction, the executive vice president now owns 54,109 shares of the company's stock, valued at $4,271,364.46. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,248 shares of company stock valued at $2,024,890. 1.75% of the stock is currently owned by corporate insiders.

Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Stock News Headlines

BioMarin Pharmaceutical (NASDAQ:BMRN) PT Raised to $117.00
BioMarin Presents Findings from Studies of...
Analyst Ratings for Biomarin Pharmaceutical
BMRN June 2023 Options Begin Trading
See More Headlines
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Company Calendar

Last Earnings
8/03/2022
Today
8/12/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BMRN
CUSIP
09061G10
Employees
3,045
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$110.93
High Stock Price Forecast
$135.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+17.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
15 Analysts

Profitability

Net Income
$-64,080,000.00
Pretax Margin
2.95%

Debt

Sales & Book Value

Annual Sales
$1.85 billion
Cash Flow
$0.85 per share
Book Value
$24.29 per share

Miscellaneous

Free Float
182,228,000
Market Cap
$17.53 billion
Optionable
Optionable
Beta
0.33

Social Links















BMRN Stock - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BMRN shares.
View BMRN analyst ratings
or view top-rated stocks.

What is BioMarin Pharmaceutical's stock price forecast for 2022?

15 equities research analysts have issued twelve-month price objectives for BioMarin Pharmaceutical's stock. Their BMRN share price forecasts range from $70.00 to $135.00. On average, they anticipate the company's stock price to reach $110.93 in the next year. This suggests a possible upside of 16.7% from the stock's current price.
View analysts price targets for BMRN
or view top-rated stocks among Wall Street analysts.

How have BMRN shares performed in 2022?

BioMarin Pharmaceutical's stock was trading at $88.35 on January 1st, 2022. Since then, BMRN stock has increased by 7.6% and is now trading at $95.07.
View the best growth stocks for 2022 here
.

When is BioMarin Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our BMRN earnings forecast
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings data on Wednesday, August, 3rd. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.04. BioMarin Pharmaceutical had a net margin of 2.83% and a trailing twelve-month return on equity of 1.78%. During the same period in the prior year, the business posted $0.23 earnings per share.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.06 billion-$2.16 billion, compared to the consensus revenue estimate of $2.11 billion.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (9.53%), Parnassus Investments LLC (1.50%), California Public Employees Retirement System (0.72%), Fort Washington Investment Advisors Inc. OH (0.67%), Clearbridge Investments LLC (0.61%) and Manning & Napier Group LLC (0.51%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends
.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $95.07.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $17.63 billion and generates $1.85 billion in revenue each year. The biotechnology company earns $-64,080,000.00 in net income (profit) each year or $0.26 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

The company employs 3,045 workers across the globe.

When was BioMarin Pharmaceutical founded?

BioMarin Pharmaceutical was founded in 1997.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.

This page (NASDAQ:BMRN) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.